Genetic aspects of adrenocortical tumours and hyperplasias

Clinical Endocrinology

Volumn 77, Issue 1, 2012, Pages 1-10

  Mazzuco, Tânia L ^a,b   Durand, Julien ^b   Chapman, Audrey ^b   Crespigio, Jefferson ^a   Bourdeau, Isabelle ^b  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; APC PROTEIN; BETA ADRENERGIC RECEPTOR; BETA CATENIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; CHORIONIC GONADOTROPIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1C; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEPTIN; LUTEINIZING HORMONE; MITOGEN ACTIVATED PROTEIN KINASE; POTASSIUM CHANNEL KCNQ1; PROTEIN P53; RAS PROTEIN; SEROTONIN 7 RECEPTOR; SOMATOMEDIN; SOMATOMEDIN B; TRANSCRIPTION FACTOR JUND; UNINDEXED DRUG; VASOPRESSIN V3 RECEPTOR;

ACROMEGALY; ADENOMATOUS POLYP; ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; ADRENAL HYPERPLASIA; ALBRIGHT SYNDROME; BECKWITH WIEDEMANN SYNDROME; BRAIN TUMOR; BREAST CANCER; CANCER STAGING; CARNEY COMPLEX; CELL PROLIFERATION; CHILDHOOD CANCER; COLON CANCER; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; CUSHING SYNDROME; DESMOID TUMOR; DNA DETERMINATION; FAMILIAL CANCER; GENE INACTIVATION; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC DISORDER; HEART MYXOMA; HEPATOBLASTOMA; HUMAN; HYPERPLASIA; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; LEUKEMIA; MACROGLOSSIA; MACROSOMIA; MEDULLOBLASTOMA; MULTIPLE ENDOCRINE NEOPLASIA; NEPHROBLASTOMA; NEURILEMOMA; OSTEOMA; OVERALL SURVIVAL; PANCREAS CARCINOMA; PARATHYROID TUMOR; PKA; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SERTOLI CELL TUMOR; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN PIGMENTATION; STOMACH POLYP; THYROID CARCINOMA; TUMOR GROWTH; WNT SIGNALING PATHWAY;

ADRENAL CORTEX NEOPLASMS; ADRENAL HYPERPLASIA, CONGENITAL; ADRENOCORTICAL ADENOMA; BECKWITH-WIEDEMANN SYNDROME; CARNEY COMPLEX; HUMANS; LI-FRAUMENI SYNDROME; MODELS, BIOLOGICAL; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NEOPLASTIC SYNDROMES, HEREDITARY;

EID: 84862014322     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2012.04403.x     Document Type: Review

References (73)

1. Li, F.P., Fraumeni Jr, J.F., Mulvihill, J.J. et al. (1988) A cancer family syndrome in twenty-four kindreds. Cancer Research, 48, 5358-5362.
2. Birch, J.M., Hartley, A.L., Tricker, K.J. et al. (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Research, 54, 1298-1304.
3. Eeles, R.A. (1995) Germline mutations in the TP53 gene. Cancer Surveys, 25, 101-124.
4. Palmero, E.I., Achatz, M.I.W., Ashton-Prolla, P. et al. (2010) Tumour protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Current Opinion in Oncology, 22, 64-69.
5. Bougeard, G., Sesboue, R., Baert-Desurmont, S. et al. (2008) Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. Journal of Medical Genetics, 45, 535-538.
6. Ribeiro, R.C., Sandrini, F., Figueiredo, B. et al. (2001) An inherited p53 mutation that contributes in a tissue-specific manner to paediatric adrenal cortical carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 98, 9330-9335. (Pubitemid 32743916)
7. Latronico, A.C., Pinto, E.M., Domenice, S. et al. (2001) An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumour suppressor protein in children and adults with sporadic adrenocortical tumours. Journal of Clinical Endocrinology and Metabolism, 86, 4970-4973. (Pubitemid 33020551)
8. Palmero, E.I., Schuler-Faccini, L., Caleffi, M. et al. (2008) Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Letters, 261, 21-25.
9. Seidinger, A.L., Mastellaro, M.J., Paschoal Fortes, F. et al. (2011) Association of the highly prevalent TP53 R337H mutation with paediatric choroid plexus carcinoma and osteosarcoma in southeast Brazil. Cancer, 117, 2228-2235.
10. Cohen Jr, M.M. (2005) Beckwith-Wiedemann syndrome: historical, clinicopathological, and etiopathogenetic perspectives. Pediatric and Developmental Pathology, 8, 287-304.
11. Elliott, M., Bayly, R., Cole, T. et al. (1994) Clinical features and natural history of Beckwith-Wiedemann syndrome: presentation of 74 new cases. Clinical Genetics, 46, 168-174. (Pubitemid 24280202)
12. Weksberg, R., Shuman, C. & Beckwith, J.B. (2010) Beckwith - Wiedemann syndrome. European Journal of Human Genetics, 18, 8-14.
13. Rump, P., Zeegers, M.P. & van Essen, A.J. (2005) Tumour risk in Beckwith-Wiedemann syndrome: a review and meta-analysis. American Journal of Medical Genetics, Part A, 136, 95-104. (Pubitemid 40934240)
14. Lapunzina, P. (2005) Risk of tumourigenesis in overgrowth syndromes: a comprehensive review. American Journal of Medical Genetics, Part C, Seminars in Medical Genetics, 137C, 53-71.
15. Taide, D.V., Bendre, P.S., Redkar, R. et al. (2010) Adrenal masses associated with Beckwith Wiedemann syndrome in the newborn. African Journal of Paediatric Surgery, 7, 209-210.
16. Alsultan, A., Lovell, M.A., Hayes, K.L. et al. (2008) Simultaneous occurrence of right adrenocortical tumour and left adrenal neuroblastoma in an infant with Beckwith-Wiedemann syndrome. Pediatric Blood & Cancer, 51, 695-698.
17. Baldisserotto, M., Peletti, A.B., Angelo de Araujo, M. et al. (2005) Beckwith-Wiedemann syndrome and bilateral adrenal pheochromocytoma: sonography and MRI findings. Pediatric Radiology, 35, 1132-1134.
18. Marini, F., Falchetti, A., Luzi, E. et al. (2009) Multiple Endocrine Neoplasia Type 1 (MEN1) Syndrome: National Center for Biotecnology Information. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21249756.
19. Newey, P.J. & Thakker, R.V. (2011) Role of Multiple Endocrine Neoplasia Type 1 (MEN1) Mutational Analysis in Clinical Practice. Endocrine Practice, 17, 1-24.
20. Piecha, G., Chudek, J. & Wiecek, A. (2008) Multiple Endocrine Neoplasia type 1. European Journal of Internal Medicine, 19, 99-103. (Pubitemid 351179292)
21. Schaefer, S., Shipotko, M., Meyer, S. et al. (2008) Natural course of small adrenal lesions in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. European Journal of Endocrinology, 158, 699-704. (Pubitemid 351639608)
22. Wu, X. & Hua, X. (2008) Menin, histone h3 methyltransferases, and regulation of cell proliferation: current knowledge and perspective. Current Molecular Medicine, 8, 805-815.
23. Harding, B., Lemos, M.C., Reed, A.A. et al. (2009) Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia. Endocrine-Related Cancer, 16, 1313-1327.
24. Skogseid, B., Larsson, C., Lindgren, P.G. et al. (1992) Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. Journal of Clinical Endocrinology and Metabolism, 75, 76-81.
25. Marchesa, P., Fazio, V.W., Church, J.M. et al. (1997) Adrenal masses in patients with familial adenomatous polyposis. Diseases of the Colon and Rectum, 40, 1023-1028. (Pubitemid 27377577)
26. Smith, T.G., Clark, S.K., Katz, D.E. et al. (2000) Adrenal masses are associated with familial adenomatous polyposis. Diseases of the Colon and Rectum, 43, 1739-1742. (Pubitemid 32001874)
27. Stratakis, C.A., Kirschner, L.S. & Carney, J.A. (2001) Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. Journal of Clinical Endocrinology and Metabolism, 86, 4041-4046. (Pubitemid 32848510)
28. Bourdeau, I., Lacroix, A., Schurch, W. et al. (2003) Primary pigmented nodular adrenocortical disease: paradoxical responses of cortisol secretion to dexamethasone occur in vitro and are associated with increased expression of the glucocorticoid receptor. Journal of Clinical Endocrinology and Metabolism, 88, 3931-3937. (Pubitemid 37034548)
29. Kirschner, L.S., Carney, J.A., Pack, S.D. et al. (2000) Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nature Genetics, 26, 89-92.
30. Griffin, K.J., Kirschner, L.S., Matyakhina, L. et al. (2004) A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumours: comparison with Carney complex and other PRKAR1A induced lesions. Journal of Medical Genetics, 41, 923-931. (Pubitemid 40007253)
31. Pereira, A.M., Hes, F.J., Horvath, A. et al. (2009) Association of the M1V PRKAR1A Mutation with Primary Pigmented Nodular Adrenocortical Disease in Two Large Families. Journal of Clinical Endocrinology & Metabolism, 95, 338-342.
32. Horvath, A., Boikos, S., Giatzakis, C. et al. (2006) A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nature Genetics, 38, 794-800.
33. Horvath, A., Mericq, V. & Stratakis, C.A. (2008) Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia. New England Journal of Medicine, 358, 750-752. (Pubitemid 351240774)
34. Libe, R., Horvath, A., Vezzosi, D. et al. (2011) Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumours. in CNC as a modifier of the phenotype. Journal of Clinical Endocrinology and Metabolism, 96, E208-E214.
35. Lacroix, A., Bourdeau, I., Lampron, A. et al. (2009) Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. Clinical Endocrinology (Oxford), 73, 1-15.
36. Gruschwitz, T., Breza, J., Wunderlich, H. et al. (2010) Improvement of histopathological classification of adrenal gland tumours. by genetic differentiation. World Journal of Urology, 28, 329-334.
37. Loncarevic, I.F., Hering, A., Posorski, N. et al. (2008) Number of genomic imbalances correlates with the overall survival for adrenocortical cancer in childhood. Pediatric Blood and Cancer, 51, 356-362.
38. Ragazzon, B., Assie, G. & Bertherat, J. (2011) Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments. Endocrine-Related Cancer, 18, R15-R27.
39. de Fraipont, F., El Atifi, M., Cherradi, N. et al. (2005) Gene expression profiling of human adrenocortical tumours. using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. Journal of Clinical Endocrinology and Metabolism, 90, 1819-1829. (Pubitemid 40464057)
40. Boulle, N., Baudin, E., Gicquel, C. et al. (2001) Evaluation of plasma insulin-like growth factor binding protein-2 as a marker for adrenocortical tumours. European Journal of Endocrinology, 144, 29-36. (Pubitemid 32126909)
41. Almeida, M.Q., Fragoso, M.C., Lotfi, C.F. et al. (2008) Expression of insulin-like growth factor-II and its receptor in paediatric and adult adrenocortical tumours. Journal of Clinical Endocrinology and Metabolism, 93, 3524-3531.
42. Ohgaki, H., Kleihues, P. & Heitz, P.U. (1993) p53 mutations in sporadic adrenocortical tumours. International Journal of Cancer, 54, 408-410. (Pubitemid 23169678)
43. Reincke, M., Karl, M., Travis, W.H. et al. (1994) p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. Journal of Clinical Endocrinology and Metabolism, 78, 790-794.
44. Libe, R., Groussin, L., Tissier, F. et al. (2007) Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clinical Cancer Research, 13, 844-850. (Pubitemid 46340358)
45. Gicquel, C., Bertagna, X., Gaston, V. et al. (2001) Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumours. Cancer Research, 61, 6762-6767. (Pubitemid 32896498)
46. Masi, G., Lavezzo, E., Iacobone, M. et al. (2009) Investigation of BRAF and CTNNB1 activating mutations in adrenocortical tumours. Journal of Endocrinological Investigation, 32, 597-600.
47. Tadjine, M., Lampron, A., Ouadi, L. et al. (2008) Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clinical Endocrinology (Oxford), 68, 264-270.
48. Tissier, F., Cavard, C., Groussin, L. et al. (2005) Mutations of beta-catenin in adrenocortical tumours.: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumours. Cancer Research, 65, 7622-7627. (Pubitemid 41297234)
49. Berthon, A., Sahut-Barnola, I., Lambert-Langlais, S. et al. (2010) Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Human Molecular Genetics, 19, 1561-1576.
50. Gaujoux, S., Pinson, S., Gimenez-Roqueplo, A.P. et al. (2010) Inactivation of the APC gene is constant in adrenocortical tumours. from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. Clinical Cancer Research, 16, 5133.
51. Tadjine, M., Lampron, A., Ouadi, L. et al. (2008) Detection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease (PPNAD). Clinical Endocrinology (Oxford), 69, 367-373.
52. Chapman, A., Durand, J., Ouadi, L. et al. (2011) Identification of Genetic Alterations of AXIN2 Gene in Adrenocortical Tumours. Journal of Clinical Endocrinology and Metabolism, 96, E1477-E1481.
53. Bonnet, S., Gaujoux, S., Launay, P. et al. (2011) Wnt/beta-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumours.: a study in cortisol-secreting and -nonsecreting tumours. Journal of Clinical Endocrinology and Metabolism, 96, E419-E426.
54. Fragoso, M.C., Domenice, S., Latronico, A.C. et al. (2003) Cushing's syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene. Journal of Clinical Endocrinology and Metabolism, 88, 2147-2151. (Pubitemid 36549891)
55. Kobayashi, H., Usui, T., Fukata, J. et al. (2000) Mutation analysis of Gsalpha, adrenocorticotropin receptor and p53 genes in Japanese patients with adrenocortical neoplasms: including a case of Gsalpha mutation. Endocrine Journal, 47, 461-466.
56. Latronico, A.C., Reincke, M., Mendonca, B.B. et al. (1995) No evidence for oncogenic mutations in the adrenocorticotropin receptor gene in human adrenocortical neoplasms. Journal of Clinical Endocrinology and Metabolism, 80, 875-877.
57. Swords, F.M., Noon, L.A., King, P.J. et al. (2004) Constitutive activation of the human ACTH receptor resulting from a synergistic interaction between two naturally occurring missense mutations in the MC2R gene. Molecular and Cellular Endocrinology, 213, 149-154. (Pubitemid 38210047)
58. Bertherat, J., Groussin, L., Sandrini, F. et al. (2003) Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumours.: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Research, 63, 5308-5319. (Pubitemid 37139845)
59. Libe, R., Fratticci, A., Coste, J. et al. (2008) Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumours. Clinical Cancer Research, 14, 4016-4024.
60. Yashiro, T., Hara, H., Fulton, N.C. et al. (1994) Point mutations of ras genes in human adrenal cortical tumours.: absence in adrenocortical hyperplasia. World Journal of Surgery, 18, 455-460; discussion 460-461.
61. Moul, J.W., Bishoff, J.T., Theune, S.M. et al. (1993) Absent ras gene mutations in human adrenal cortical neoplasms and pheochromocytomas. Journal of Urology, 149, 1389-1394. (Pubitemid 23164527)
62. Ocker, M., Sachse, R., Rico, A. et al. (2000) PCR-SSCP analysis of human adrenocortical adenomas: absence of K-ras gene mutations. Experimental and Clinical Endocrinology & Diabetes, 108, 513-514.
63. Heppner, C., Reincke, M., Agarwal, S.K. et al. (1999) MEN1 gene analysis in sporadic adrenocortical neoplasms. Journal of Clinical Endocrinology and Metabolism, 84, 216-219. (Pubitemid 29036705)
64. Ferraz-de-Souza, B., Lin, L. & Achermann, J.C. (2011) Steroidogenic factor-1 (SF-1, NR5A1) and human disease. Molecular and Cellular Endocrinology, 336, 198-205.
65. Almeida, M.Q., Soares, I.C., Ribeiro, T.C. et al. (2010) Steroidogenic factor 1 overexpression and gene amplification are more frequent in adrenocortical tumours. from children than from adults. Journal of Clinical Endocrinology and Metabolism, 95, 1458-1462.
66. Sbiera, S., Schmull, S., Assie, G. et al. (2010) High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumours. Journal of Clinical Endocrinology and Metabolism, 95, E161-E171.
67. Kotoula, V., Sozopoulos, E., Litsiou, H. et al. (2009) Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocrine-Related Cancer, 16, 565-572.
68. Adam, P., Hahner, S., Hartmann, M. et al. (2010) Epidermal growth factor receptor in adrenocortical tumours.: analysis of gene sequence, protein expression and correlation with clinical outcome. Modern Pathology, 23, 1596-1604.
69. Mazzuco, T.L., Chabre, O., Feige, J.J. et al. (2007) Aberrant GPCR expression is a sufficient genetic event to trigger adreno-cortical tumourigenesis. Molecular and Cellular Endocrinology, 265-266, 23-28. (Pubitemid 46273976)
70. Barlaskar, F.M., Spalding, A.C., Heaton, J.H. et al. (2008) Pre-clinical Targeting of the Type I Insulin-Like Growth Factor Receptor in Adrenocortical Carcinoma. Journal of Clinical Endocrinology & Metabolism, 94, 204-212.
71. Haluska, P., Worden, F., Olmos, D. et al. (2010) Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemotherapy and Pharmacology, 65, 765-773.
72. Doghman, M., Cazareth, J., Douguet, D. et al. (2009) Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists. Journal of Clinical Endocrinology and Metabolism, 94, 2178-2183.
73. Doghman, M., Cazareth, J. & Lalli, E. (2008) The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. Journal of Clinical Endocrinology and Metabolism, 93, 3222-3225.